NCT04971226 2026-04-06
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
Novartis
Phase 3 Active not recruiting
Clinical Trials
6 trialsNCT04948333 2026-03-18
Asciminib Treatment Optimization in ≥ 3rd Line CML-CP
Novartis
Phase 3 Completed
NCT05456191 2026-02-06
ASC4START
Novartis
Phase 3 Active not recruiting
NCT04666259 2025-10-16
AIM4CML
Novartis
Phase 3 Completed
NCT05413915 2025-05-21
Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML
Sir Mortimer B. Davis - Jewish General Hospital
Phase 3 Active not recruiting
NCT03106779 2025-04-08
Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs
Novartis
Phase 3 Completed